FTC, seven states seek contempt ruling against Martin Shkreli over pharma ban
The FTC and seven US states have asked a court to hold Martin Shkreli in contempt for allegedly breaching his lifetime pharma industry ban.
What happened
The FTC and seven US states have filed a motion in US district court in New York alleging that Martin Shkreli violated a lifetime ban on participating in the pharmaceutical industry.12
The FTC alleges Shkreli traded stocks in at least 60 pharmaceutical companies, in breach of his 2022 release conditions.1
Shkreli said in a livestream, "I can always find a couple of biotech stocks to smoke," according to Ars Technica, which reported the FTC cited this as evidence of ban violations.3
Regulators and media describe Shkreli, previously nicknamed the Pharma Bro, as facing renewed regulatory trouble for allegedly influencing biopharma stocks despite his ban.4
What's agreed
Reported consistently by outlets in more than one region.
- Martin Shkreli is subject to a lifetime ban from participating in the pharmaceutical industry under his 2022 release conditions.13
- The FTC is seeking to have Shkreli held in contempt of court for allegedly violating that ban.123
- The FTC alleges Shkreli has been trading or weighing in on biopharma and pharmaceutical stocks despite the ban.134
How it's framed
What each perspective puts first, based on headlines and summaries.
| Perspective | How it reads | What it puts first |
|---|---|---|
| US trade and tech pressNorth America | US outlets STAT, Ars Technica and MarketWatch frame the story around regulatory action and specific alleged evidence, including a livestream and direct FTC language.234 | FTC contempt motion, livestreamed comments, regulatory trouble |
| UK general-interest pressEurope | The Guardian, the only UK outlet reviewed, frames the story with more context on Shkreli's release conditions and provides a specific figure for the number of companies involved.1 | lifetime ban, 60 companies, multi-state legal action |
What the coverage leaves out
- None of the outlets reviewed reported Shkreli's response to the allegations.
- None of the outlets reviewed detailed what specific penalties or next steps a contempt ruling could bring.
- None of the outlets reviewed specified which seven US states joined the FTC in the motion.
Why it matters
Shkreli, known as the "Pharma Bro," became a notorious figure after past pharmaceutical pricing controversies, and his 2022 release conditions barred him from industry involvement, including stock ownership or business decisions.1
What to watch
- How the US district court in New York rules on the FTC's contempt motion.
- Whether Shkreli or his legal representatives issue a public response to the allegations.
Sources (4)
Every outlet we drew on, grouped by where it is based. Read the originals for the full reporting.
North America
- 2STATUSPrivate
- 3Ars TechnicaUSPrivate
Martin Shkreli livestreamed himself violating lifetime pharma ban, FTC says
- 4MarketWatchUSPrivate
Europe
- 1The GuardianGBPrivate
FTC and seven states seek contempt ruling against Shkreli over pharma ban